Comparer des méthodes

	Formulation par dispersion solide	Facteur de similarité f1/f2 pour la dissolution	Administration de médicaments par voie liposomale
Domaine	Pharmacologie	Pharmacologie	Pharmacologie
Famille	Process / pipeline	Process / pipeline	Process / pipeline
Année d'origine	1971	1996	1965
Auteur d'origine	William Chiou and Solomon Riegelman	James Moore and Hector Flanner	Alec Bangham
Type	solubility enhancement	similarity testing	formulation technology
Source fondatrice	Chiou, W. L., Riegelman, S. (1971). Pharmaceutical applications of solid dispersions. Journal of Pharmaceutical Sciences, 60(9), 1281-1302.	Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20(6), 64-74.	Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipid films and the determination of membrane potential. Journal of Molecular Biology, 13(1), 238-252.
Alias	solid solution, amorphous dispersion, polymer-based formulation	f1, f2, similarity factor	liposomal formulation, vesicular delivery, lipid nanoparticles
Apparentées	3	3	3
Résumé	Solid dispersion is a formulation technique where a poorly soluble drug is molecularly dispersed in a hydrophilic polymer matrix, improving aqueous solubility and bioavailability. Introduced by Chiou and Riegelman in 1971, solid dispersions remain a key strategy for overcoming solubility-limited absorption.	The f1 and f2 factors are dimensionless statistical measures developed by Moore and Flanner to quantify the similarity between two dissolution profiles. Adopted by regulatory agencies (FDA, EMA) as the gold standard for comparing dissolution curves, these factors enable rapid assessment of whether formulation changes significantly impact drug release.	Liposomal encapsulation is a formulation technique using lipid bilayer vesicles (liposomes) to enclose drugs, improving bioavailability, reducing toxicity, and enabling targeted delivery. Developed by Alec Bangham in 1965, liposomes are now standard in pharmaceutical development, with several FDA-approved liposomal drugs on the market.